Management of benign prostatic hyperplasia as a day case

What is the problem?

Benign prostatic hyperplasia (BPH) is the medical term for an enlarged prostate. It is a common and chronic condition that effects more than one in three men in their 50s and costs the NHS £472 million per year. BPH can make it difficult for a man to pass urine, leading to urinary tract infections, urinary retention, and in some cases renal failure.

According to available evidence, what is the suggested solution?


Prostatic urethral lift systems are an alternative to existing surgical treatments. Current treatments such as transurethral resection of the prostate (TURP), involve cutting away or removing existing tissue. They require an average hospital stay of three days and patients will often need a catheter for many days post-surgery.

Urethral lift systems use adjustable, permanent implants to pull excess prostatic tissue away so that it does not narrow or block the urethra. Following the procedure, patients return home after a few hours, typically without the need for a catheter, and follow-up is normally by telephone. Patients have significantly fewer side effects and post-operative complications, such as infection and bleeding, compared with existing alternatives. Notably there is 0% risk of permanent sexual dysfunction. The procedure is increasingly carried out under a local anesthetic.


Urolift by Neotract is an example of a urethral lift system. Further information can be found on the Urolift website.

You can also read more about Urolift and the evidence base for urethral lift systems by following the related links on the right.

Where do I find out more about implementation?

This innovation is available on the existing tariff at similar cost to the current surgical treatment.

For an Implementation Toolkit and further information on how to get started, contact James Wright, UK & Ireland Country Manager, Neotract on


Go back to Innovation and Technology Tariff